74.58 +0.01 (0.01%)
After hours: 5:38PM EDT
|Bid||74.53 x 1800|
|Ask||74.56 x 800|
|Day's Range||73.68 - 75.45|
|52 Week Range||30.04 - 92.18|
|Beta (3Y Monthly)||1.02|
|PE Ratio (TTM)||109.66|
|Earnings Date||Apr 30, 2019 - May 6, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||79.86|
Geron (GERN) posts loss in line with the estimate in fourth-quarter 2018 but beats on revenues. Operating expenses increase on a year-over-year basis.
Sarepta (SRPT) misses estimates for both earnings and sales in fourth-quarter 2018. However, Exondys 51 performs well on strong demand.
PRESS RELEASE: REGULATED INFORMATION Thursday, 28 February 2019, 07:00 CET BIOCARTIS ANNOUNCES 2018 RESULTS AND 2019 OUTLOOK Mechelen, Belgium , 28 February 2019 - Biocartis Group NV (the `Company` ...
Arena Pharmaceuticals (ARNA) outpaces earnings estimates in Q4. Also, the top line surpasses the consensus mark. Shares Up.
Genomic Health (GHDX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Genomic Health stock toppled Thursday after the company offered a big beat on fourth-quarter sales, but earnings were mixed. An analyst says investors are nitpicking gross margins.
Genomic Health's (GHDX) year-over-year rise in revenues, driven by a solid uptick in the United States and internationally, makes us optimistic about the stock.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 20) Amphastar Pharmaceuticals Inc (NASDAQ: AMPH ) Gossamer ...
Synopsys signaled a breakout after topping views, one of four top stocks moving on earnings. Nike fell after a top college basketball player injured himself as his Nike shoe disintegrated.
Genomic Health (GHDX) delivered earnings and revenue surprises of 6.67% and 2.73%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Redwood City, California-based company said it had profit of 23 cents. Earnings, adjusted for non-recurring costs, came to 32 cents per share. The results topped Wall Street expectations. ...
Delivered $394.1M in Full-year Revenue and Growth of 18 Percent for the Full Year Reported Full-year Profit of $25.7M on a GAAP Basis and $39.7M on a Non-GAAP Basis Achieved 14th Consecutive Quarter of ...
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 19) Alector Inc (NASDAQ: ALEC ) (IPOed early February) ...
REDWOOD CITY, Calif. , Feb. 13, 2019 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that the company will host a conference call and webcast on Wednesday, February 20 at 4:30 p.m. ...
Published in Urology, the study results prospectively validated the GPS test as an independent predictor of adverse pathology at the time of surgery as a measure of disease aggressiveness for men with clinically low- or intermediate-risk prostate cancer.